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Abstract
Trypsin-containing topical treatments can be used to speed wound healing, although the mechanism of action is unknown.
To help form granulation tissue and heal wounds, monocytes leave the circulation, enter the wound tissue, and differentiate
into fibroblast-like cells called fibrocytes. We find that 20 to 200 ng/ml trypsin (concentrations similar to those used in
wound dressings) potentiates the differentiation of human monocytes to fibrocytes in cell culture. Adding trypsin inhibitors
increases the amount of trypsin needed to potentiate fibrocyte differentiation, suggesting that the potentiating effect is
dependent on trypsin proteolytic activity. Proteases with other site specificities such as pepsin, endoprotease GluC, and
chymotrypsin do not potentiate fibrocyte differentiation. This potentiation requires the presence of albumin in the culture
medium, and tryptic fragments of human or bovine albumin also potentiate fibrocyte differentiation. These results suggest
that topical trypsin speeds wound healing by generating tryptic fragments of albumin, which in turn potentiate fibrocyte
differentiation.
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Introduction
The failure of wounds to heal properly constitutes a major
medical problem, with both acute and chronic wounds consuming
treatment time and resources. Between 25–40% of hospital
patients receive treatment for either an acute or chronic wound
[1–5]. Poorly-healing chronic wounds affect more than 6.5 million
US patients per year, and cost more than $25 billion to treat [6].
Chronic wounds resist conventional wound-dressing treatments
and often occur in elderly, obese, immuno-compromised, or
diabetic patients [6,7].
Monocytes are circulating cells that are recruited to wounds and
sites of tissue injury by chemokines [8,9]. To help heal wounds,
monocytes enter the wounded tissue and differentiate into
fibroblast-like cells called fibrocytes [10,11]. Fibrocytes are
collagen-expressing CD45+ cells which assist in scar tissue
formation, a key component of both wound healing and fibrosing
diseases [10,12–14] and the development of the body’s desmo-
plastic response to foreign or invasive bodies [12,15]. Increasing
fibrocyte differentiation within a wound healing environment
potentiates wound healing, and decreasing fibrocyte differentiation
leads to slower wound healing [16]. Monocytes isolated from
peripheral blood mononuclear cells differentiate in vitro in a
defined media into fibrocytes [17]. The differentiation can be
modulated by factors such as the serum protein Serum Amyloid P
(SAP), salt concentration, cytokines such as interleukins 4, 12, and
13 and interferon, or hyaluronic acid [18–21]. Increased fibrocyte
differentiation correlates with increased fibrosis and wound
healing in animal models [16,22].
After wounding, the blood clots, leaving serum on the wound.
Albumin is the most common protein in serum, with levels
between 35–50 g/L and accounting for ,50% of the total protein
in blood [23]. Albumin is produced in the liver and maintains
blood homeostasis [23]. Increased albumin levels are associated
with increased wound healing in both acute [24] and chronic
wounds [25–27].
Trypsin, chymotrypsin, and pepsin are mammalian proteolytic
enzymes. Each is secreted as a zymogen, and later cleaved to an
active form. Each also cuts at a different amino acid pattern.
Trypsin is a proteolytic enzyme that cuts at lysine or arginine
residues, except when the following amino acid is proline [28].
Chymotrypsin preferentially cleaves following the aromatic amino
acids tyrosine, tryptophan, or phenylalanine [29]. Pepsin cuts
preferentially between hydrophobic and aromatic amino acids
[30]. Endoproteinase Glu-C is a protease isolated from Staphylo-
coccus aureus which cleaves at glutamic or aspartic acid [31,32].
Although trypsin is generally thought of as a digestive enzyme,
trypsin is also active in multiple cellular processes, including
development and tumor invasion [33–42]. Trypsin is involved in
gastric inflammation through cleavage of the proteinase-activated
receptors (PAR1–4) [43–45], and PAR1 and PAR2 digestion has
also been implicated in cancer signaling [46,47]. Topical
application of trypsin has been used to potentiate healing of both
conventional and chronic wounds for more than 50 years after
having been initially tested as a burn debridement treatment [48–
54]. In this report, we show that trypsin potentiates fibrocyte
differentiation, suggesting a mechanism of action for the effect of
trypsin on wound healing.
Materials and Methods
Cell Isolation and Exposure of PBMCs to Proteases and
Inhibitors
Human blood was collected from adult volunteers who gave
written consent and with specific approval from the Texas A&M
University human subjects Institutional Review Board. Peripheral
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blood mononuclear cells (PBMC) and monocytes were isolated as
previously described [18], and monocytes were checked for
enrichment by flow cytometry in comparison to the un-enriched
PBMC population [55]. Cells were cultured in Fibrolife basal
media as previously described [17], in either protein-free media
(PFM) or serum-free media (SFM). PFM is composed of Fibrolife
basal media (Lifeline Cell Technology, Walkersville, MD) supple-
mented with 10 mM HEPES (Sigma), 16non-essential amino
acids (Sigma), 1 mM sodium pyruvate (Sigma), 2 mM glutamine
(Lonza), 100 U/ml penicillin and 100 mg/ml streptomycin
(Lonza). SFM is composed of PFM supplemented with 16ITS-3
(500 mg/ml bovine serum albumin, 10 mg/ml insulin, 5 mg/ml
transferrin, 5 ng/ml sodium selenite, 5 mg/ml linoleic acid, and
5 mg/ml oleic acid, (Sigma). Where indicated, PFM was supple-
mented with recombinant insulin suitable for cell culture (Sigma),
transferrin suitable for cell culture (Sigma), or human or bovine
albumin to the above concentrations, or 12.5% human serum.
TPCK is an irreversible inhibitor of chymotrypsin, and TLCK is
an irreversible inhibitor of trypsin. TPCK-treated trypsin (Sigma),
TLCK-treated chymotrypsin (Sigma), pepsin from porcine stom-
ach mucosal lining (EMD), or endoproteinase Glu-C from S. aureus
(Sigma) were all resuspended to 10 mg/ml following the manu-
facturer’s instructions. Complete protease inhibitor cocktail
(Roche, Indianapolis, IN) was resuspended to 40 mg/ml in water,
and soybean trypsin inhibitor (Sigma) was resuspended to 10 mg/
ml in water. Fibrocytes were stained, identified and counted as
previously described [56].
Purification of Albumin
Albumin was purified from sterile filtered non-blood type
specific human serum, tested negative for hepatitis A and B and
HIV I and II (Lonza, Basel, Switzerland and Gemini Bio-products,
West Sacramento, California) or from triple filtered US origin fetal
calf serum, tested for sterility and mycoplasma (Thermo Fisher
Scientific, Milwaukee, WI) by affi-gel bead affinity elution (Bio-
Rad, Hercules, California). 4 ml of beads were washed three times
in 25 ml PBS, and were added to 40 ml of serum with gentle
mixing at room temperature for 2 hours. The beads were collected
by centrifugation at 3006g for 5 minutes and washed three times
with 25 ml of filter-sterilized buffer (20 mM Tris, 140 mM NaCl,
2 mM CaCl2 pH 8.0) and eluted overnight with gentle mixing in
25 ml of 0.5 M NaCl. The beads were then removed by
centrifugation at 3006g for 5 minutes. The 0.5 M NaCl solution
containing the eluted albumin was then buffer exchanged three
times through a 10 kDa filter (EMD Millipore, Billerica, MD)
using 15 ml Earle’s balanced salt solution (EBSS buffer) (Sigma,
St. Louis, MO), tested for concentration using by absorbance at
280 nm, and diluted to a final concentration of 25 mg/ml in EBSS
and stored at 4uC. Samples were diluted 1:10 in 20 mM sodium
phosphate buffer, pH 7.2, and run on 4–20% SDS gels (Bio-Rad,
Hercules, California), which were silver stained to check for
albumin purity.
Depletion of Albumin
Albumin was depleted from human serum by affi-gel bead
affinity elution (Bio-Rad). 500 ml of beads were washed three times
in 2 ml PBS, and were added to 2 ml of serum with gentle mixing
at room temperature for 2 hours. The beads were removed by
centrifugation at 3006g for 5 minutes and the albumin depletion
was repeated as above twice more. Samples were diluted 1:10 in
20 mM phosphate buffer and run on 4–20% SDS gels which were
silver stained to show differences in protein concentrations. Serum
and depleted serum were diluted to 1:100 and 1:10 concentrations,
respectively, and western blots were stained with mouse mono-
clonal anti human-albumin antibody, clone HSA-11, following the
manufacturer’s instructions (Sigma).
Trypsin Digest Products Added to Culture
TPCK-treated trypsin-coated agarose beads (Sigma) were
washed according to the manufacturer’s instructions. To digest
serum or albumin, 12.5 ml of beads was mixed with 250 ml of
serum, 25 mg/ml albumin, 250 ml SFM containing 500 mg/ml
human albumin or bovine albumin, or 250 ml serum-free
medium containing 10 mg/ml insulin or 5 mg/ml transferrin.
Beads were incubated with gentle rotation at 37˚C for 2 hours,
and were removed by centrifugation at 3006g for 5 minutes.
The digested media and undigested controls were mixed with
PFM or SFM supplemented with bovine albumin. In experi-
ments where human albumin was digested, the trypsinized
human albumin and untrypsinized human albumin controls
were, if indicated, mixed with SFM supplemented with human
albumin.
Collagen Staining by Flow Cytometry
24-well tissue culture treated plates (BD Bioscience, San Jose,
CA) were coated for 1 hour at 37uC with 20 mg/ml human
cellular fibronectin from fibroblasts (Sigma) in PBS and gently
rinsed twice with sterile PBS. 500 ml of PBMC at 16106 cells/
ml in SFM was added to each well. Control wells were
supplemented with 250 ml SFM containing 500 mg/ml human
albumin, while sample wells were supplemented with SFM
digested by TPCK-treated trypsin-coated agarose beads as
described above. After 5 days, cells were washed with warm
PBS and exposed to 125 ml accutase (Innovative Cell Technol-
ogies, San Diego, CA) for 20 minutes at 37uC. Cells were
resuspended via gentle pipetting, and washed by suspension in
1 ml ice cold PBS, collected by centrifugation at 3006g for 5
minutes, then washed once more. Cells were resuspended in 1%
paraformaldehyde/0.2% saponin/PBS for 15 minutes on ice,
washed twice as above, and resuspended in 2% BSA/0.2%
saponin/PBS for 15 minutes of blocking. Anti-collagen type I
rabbit (Rockland, Gilbertsville, PA) and control rabbit IgG
(Jackson Immunoresearch, West Grove, PA) antibodies were
added to the cell suspensions at 1 mg/ml and incubated on ice
for 30 minutes. Cells were washed twice with ice cold PBS and
resuspended in 4 mg/ml goat anti-rabbit alexa-fluor 488
secondary antibody (Molecular Probes, Eugene, OR) for 30
minutes on ice. Cells were washed twice and resuspended in ice
cold PBS and analyzed with an Accuri C6 flow cytometer for
fluorescence. Negative controls were used to set gates.
Statistical Analysis
Statistics were performed using Prism (Graphpad software, San
Diego, CA). Differences among multiple groups were assessed by
1-way ANOVA (with Dunnett’s post test), and between two groups
by a two-tailed Mann-Whitney t-test. Significance was defined by
p,0.05.
Results
Trypsin Treatment Increases Fibrocyte Number
Topical treatment with trypsin improves wound healing,
although the mechanism is unknown [48–54]. The differentia-
tion of monocytes into fibrocytes plays a role in wound healing
[10–12,14]. To test the hypothesis that trypsin increases wound
healing by potentiating fibrocyte differentiation, we examined
the effect of trypsin on fibrocyte differentiation in culture.
Human peripheral blood mononuclear cells (PBMC) were
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incubated with trypsin for 5 days in a defined serum-free
medium. The cells were then stained and scored for fibrocyte
formation. Fibrocyte numbers were normalized to trypsin-free
controls due to variability in donors as we previously observed
[17–20,56]. Trypsin concentrations between 20 and 150 ng/ml
significantly increased the number of fibrocytes (Figure 1A), and
this effect was observed for all donors tested. Trypsin
concentrations above 1000 ng/ml decreased the number of
fibrocytes. The number of adherent cells following fixing and
staining was not significantly affected by trypsin (Figure 1B),
suggesting that trypsin specifically increases the number of
differentiated fibrocytes, rather than increasing the general cell
viability or adhesion. This suggests that trypsin can potentiate
fibrocyte differentiation.
Other Proteases do not Increase Fibrocyte Number
To determine if other proteases also potentiate fibrocyte
differentiation, we examined the effect of three other proteases.
Pepsin and endoproteinase Glu-C had no significant effect on
fibrocyte differentiation or the number of adhered PBMC
(Figure 2A and B). Chymotrypsin at 5000 ng/ml and above
caused lower fibrocyte numbers and lower numbers of adhered
PBMC (Figure 2A and 2B). These results suggest that not all
proteases potentiate fibrocyte differentiation, and that a specific
aspect of the protein structure or activity of trypsin is responsible
for trypsin potentiating fibrocyte formation.
Trypsin’s Enzymatic Activity causes Fibrocyte
Potentiation
To determine whether trypsin’s enzymatic activity is necessary
to potentiate fibrocyte formation, we examined the effect of two
trypsin inhibitors on the ability of trypsin to potentiate fibrocyte
differentiation. Adding trypsin inhibitors alone to cultures of
PBMC had no significant effect on fibrocyte differentiation, with
the exception of 4 ml/ml protease inhibitor cocktail, which
decreased overall fibrocyte formation (Figure 3A). The addition
of soybean trypsin inhibitor (Figure 3B) or protease inhibitor
cocktail (Figure 3C) increased the amount of trypsin needed to
potentiate fibrocyte differentiation. Increasing the inhibitor
concentration increased the concentration of trypsin necessary to
double fibrocyte differentiation compared to the controls (Arrows,
Figures 3B and 3C). Pre-incubating trypsin and inhibitor
completely abrogated trypsin’s potentiation of fibrocyte differen-
tiation (data not shown). Together, these results suggest that the
protease activity of trypsin affects its ability to potentiate fibrocyte
differentiation.
Figure 1. Trypsin potentiates fibrocyte differentiation. (A) PBMC
were cultured in serum free media in the presence of the indicated
concentrations of trypsin for 5 days, after which the PBMC were air-
dried, stained, counted for fibrocyte differentiation, and normalized for
each donor to the no-trypsin control. The no-trpysin controls developed
41.865.4 fibrocytes per 105 PBMC. (B) The same PBMC populations
were then counted for the total number of PBMC adhered to the plate
following fixing and staining and normalized for each donor to the no-
trypsin control. There were no significant differences in the numbers of
adhered PBMC following fixing and staining. Values in A and B are mean
6 SEM, n = 9. **indicates p,.01 and ***indicates p,.001 compared to
the no-trypsin control by 1-way ANOVA, Dunnett’s test.
doi:10.1371/journal.pone.0070795.g001
Figure 2. Chymotrypsin, pepsin, and endoproteinase GluC do
not potentiate fibrocyte differentiation. (A) PBMC were cultured
with the indicated concentrations of protease for 5 days, and fibrocytes
were counted as in figure 1. (B) The same PBMC populations were then
counted for the total number of PBMC adhered to the plate following
fixing and staining, and normalized to the no-protease control. At high
concentrations, chymotrypsin significantly lowered the numbers of
fibrocytes and adhered PBMC. Values are mean 6 SEM, n = 9 for pepsin
and endoproteinase GluC, and n= 7 for chymotrypsin. *indicates p,.05,
**indicates p,.01, and ***indicates p,.001 compared to the no-
protease control by 1-way ANOVA, Dunnett’s test.
doi:10.1371/journal.pone.0070795.g002
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Albumin is Necessary for Trypsin to Potentiate Fibrocyte
Differentiation
To test the hypothesis that trypsin acts on a protein supplement
in the media to potentiate fibrocyte differentiation, we removed
the protein supplements from our defined medium and added
trypsin to this protein-free media. According to the manufacturer,
Fibrolife medium is protein-free. Trypsin added to Fibrolife media
lacking all three protein supplements (albumin, insulin and
transferrin) did not potentiate fibrocyte differentiation
(Figure 4A). At concentrations of 5 mg/ml and higher, trypsin
significantly decreased both fibrocyte numbers and the number of
adhered cells (Figures 4A and 4B), presumably by decreasing cell
adhesion. These results suggest that trypsin acts on a protein
supplement to indirectly potentiate fibrocyte differentiation, or
that a protein supplement is necessary for trypsin’s potentiation to
occur.
Serum-free media contains three proteins: insulin, transferrin,
and albumin. To determine whether insulin, transferrin or
albumin potentiates fibrocyte differentiation when exposed to
trypsin, we purified human and bovine albumin and made media
containing only insulin, transferrin, or albumin. When TPCK-
treated trypsin-coated agarose beads were used to trypsinize
Figure 3. Trypsin inhibitors increase the amount of trypsin
needed to potentiate fibrocyte potentiation. Trypsin inhibitors
were added to PBMC cultures at the beginning of the 5-day incubation
period at the indicated concentrations, with and without trypsin
present. PBMC were then air dried, stained, counted for fibrocyte
differentiation, and normalized to the no-trypsin control. (A) Trypsin
inhibitors did not significantly affect fibrocyte differentiation with the
exception of 4 ml/ml Roche inhibitor, which decreased fibrocyte
formation. **indicates p,.01 compared to the inhibitor-free control.
(B) Soybean trypsin inhibitor inhibited trypsin-induced fibrocyte
potentiation. No-inhibitor data is the same as figure 1A. Fibrocyte
counts were normalized to the inhibitor-containing trypsin-free control.
Arrows indicate the lowest trypsin concentrations that doubled the
fibrocyte number. Compared to the no-trypsin control, there was a
significant increase in the number of fibrocytes with p,.05 for 4 ml/ml
inhibitor for 10,000 ng/ml and at 1 ml/ml inhibitor for 5,000 ng/ml, and
p,.001 at 1 ml/ml inhibitor for 2,500 and 10,000 ng/ml and at 0.1 ml/ml
inhibitor for 2500 and 5,000 ng/ml (1-way ANOVA, Dunnett’s test). (C)
Roche complete protease inhibitor cocktail inhibitor in the cell culture
medium also inhibited trypsin-induced fibrocyte potentiation. No-
inhibitor data is the same as figure 1A. Arrows indicate the lowest
trypsin concentrations that doubled the fibrocyte number. Compared
to the no-trypsin control, there was a significant increase in the number
of fibrocytes with p,.05 at 4 ml/ml inhibitor for 1250 ng/ml and 0.1 ml/
ml inhibitor for 1250 and 2500 ng/ml, p,.01 at 1 ml/ml inhibitor for
10,000 ng/ml and at 0.1 ml/ml inhibitor for 10,000 ng/ml, and p,.001 at
4 ml/ml inhibitor for 2500, 5000, and 10,000 ng/ml (1-way ANOVA,
Dunnett’s test). Values are mean 6 SEM, n= 7.
doi:10.1371/journal.pone.0070795.g003
Figure 4. Trypsin does not potentiate fibrocyte differentiation
in medium lacking protein supplements. (A) PBMC were cultured
with the indicated concentrations of trypsin for 5 days in protein-free
medium, after which the PBMC were air-dried, stained, counted for
fibrocyte differentiation, and normalized to the no-trypsin control. The
no-trypsin controls developed 3967.2 fibrocytes per 105 PBMC. (B) The
same PBMC populations were then counted for the total number of
PBMC adhered to the plate following fixing and staining. Values are
mean 6 SEM, n = 7. *indicates p,.05, **indicates p,.01, and
***indicates p,.001 compared to the no-trypsin control by 1-way
ANOVA, Dunnett’s test.
doi:10.1371/journal.pone.0070795.g004
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culture media containing purified human or bovine albumin, the
trypsinized media potentiated fibrocyte formation following the
removal of the beads and addition to PBMC (Figure 5A).
Fibrocyte potentiation did not occur after the addition of
protein-free, insulin-containing, or transferrin-containing media
trypsinized in the same fashion (Figure 5A). To verify that TPCK
did not influence fibrocyte differentiation, we digested human-
albumin containing SFM with non TPCK-treated trypsin beads.
Media containing human albumin digested by non TPCK-treated
trypsin-beads also potentiated fibrocyte differentiation (Figure 5B).
Using trypsin-coated beads to directly digest bovine and human
albumin into fragments, and then adding those fragments to
protein-free medium also potentiated fibrocyte differentiation
compared to undigested controls (Figure 6A). SDS-PAGE gels
indicated that the protease treatment of albumin caused the
formation of digestion products (Figure 6B). These results suggest
that a trypsin fragment of albumin may potentiate fibrocyte
differentiation.
Figure 5. Serum-free medium containing albumin potentiates
fibrocyte differentiation after temporary mixing with trypsin-
coated agarose beads. TPCK-treated trypsin-coated agarose beads
were used to digest protein-free culture media (PFM) and PFM
containing bovine albumin, human albumin, transferrin, or insulin,
after which the beads were removed. Digested media and controls
were mixed with SFM at the indicated percentages and added to PBMC
at the beginning of a 5 day incubation, after which the PBMC were air-
dried, stained, counted for fibrocyte differentiation, and normalized to
the control media containing the same amount of undigested protein.
(A) After removal of the beads, only medium containing albumin
fragments potentiated fibrocyte differentiation. Values are mean 6
SEM, n = 3 for protein-free medium (PFM), insulin, and transferrin, n = 4
for bovine albumin, and n=7 for human albumin. Compared to the
human albumin control, digested human albumin significantly
increased the number of fibrocytes with p,.05 at 62 mg/ml, p,.01 at
250 mg/ml, and p,.001 at 500 mg/ml. Compared to the bovine albumin
control, digested bovine albumin increased the number of fibrocytes
with p,.05 at 31 mg/ml, p,.01 at 250 mg/ml, and p,.001 at 500 mg/ml
(1-way ANOVA, Dunnett’s test). (B) Human albumin-containing media
potentiated fibrocyte differentiation when digested by non-TPCK
treated trypsin-coated agarose beads. Values are mean 6 SEM, n= 3.
*indicates p,.05 and **indicates p,.01 compared to the human
albumin control by 1-way ANOVA, Dunnett’s test.
doi:10.1371/journal.pone.0070795.g005
Figure 6. Albumin potentiates fibrocyte differentiation after
temporary mixing with trypsin-coated agarose beads. TPCK-
treated trypsin-coated agarose beads were used to digest bovine or
human albumin. After the beads were removed, the digested albumin
was added to PBMC cultures in SFM at the indicated concentrations for
5 days, after which the PBMC were air-dried, stained, counted for
fibrocyte differentiation, and normalized to the bovine or human
albumin controls. Values are mean 6 SEM, n = 4, **indicates p,.01 and
***indicates p,.001 for both bovine and human albumin compared to
the no-albumin control (1-way ANOVA, Dunnett’s test). (B) 250 ml of
protein-free media supplemented with human albumin was digested
for two hours with gentle rotation at 37uC with 1 mg/ml protease,
0.1 mg/ml protease, or with 12.5 mg/ml TPCK-treated trypsin-coated
agarose beads. Samples were then run on a 7.5% SDS-PAGE gel and
silver stained. PFM indicates protein free medium, CT indicates
chymtotrypsin, and Glu-C indicates endoprotease Glu-C. Alternative
prep indicates samples from a repeat of this experiment that happened
to be included in this gel. This gel is a digestion of human albumin, and
is representative of similar gels of digestions of medium containing
bovine albumin or ITS-3.
doi:10.1371/journal.pone.0070795.g006
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Increased Fibrocyte Numbers are Associated with
Increased Collagen Expression
Increased collagen expression in a PBMC culture is a marker for
increased fibrocyte differentiation [10,11,55]. To determine
whether trypsinized human albumin increases collagen-positive
cells, we resuspended and stained PBMC with an anti-collagen
antibody following our 5-day differentiation assay. Increased
collagen expression was detected by flow cytometry in PBMC
cultures incubated with trypsinized human albumin (Figures 7A).
A representative flow plot can be seen in Figure 7B. This suggests
that the albumin fragment-induced increase in fibrocyte number is
accompanied by an increase in collagen expression.
Trypsinized Albumin Increases Fibrocyte Formation in an
Enriched Monocyte Population
Fibrocytes differentiate from monocytes [10,12,17]. Cells in a
PBMC population can include T-cells, B-cells, or NK cells [20].
To determine whether trysinized albumin acts directly on
monocytes to potentiate fibrocyte differentiation, as opposed to
an indirect action through other cells in the PBMC population, we
isolated monocytes by negative selection from an average of 16%
to an average of 83% purity. When added to the monocyte-
enriched cells, 70 mg/ml trypsinized albumin potentiated fibrocyte
differentiation by 223% 69% (n = 3; p,0.01, t-test). This suggests
that tryptic fragments of albumin act directly on monocytes to
potentiate fibrocyte differentiation.
Trypsinizing Albumin-containing Serum Promotes
Fibrocyte Differentiation
In a wound environment, monocytes and exogenous trypsin
would be exposed to serum. Human serum contains more than
500–1200 proteins, of which the primary component is albumin
[57,58]. To determine whether trypsin potentiates fibrocyte
differentiation when mixed with human serum, we digested
human serum with trypsin, and then added these digestion
products to PBMCs. As previously observed [20], human serum
Figure 7. Collagen production is increased in PBMC exposed to trypsinized albumin. (A) TPCK-treated trypsin-coated agarose beads were
used to digest protein-free media and media containing human albumin. After the beads were removed, the media was added to PBMC cultures in
serum-free medium at a 33% concentration. Cells were exposed to trypsinized human albumin for 5 days, then resuspended, stained with anti-
collagen and alexa-fluor secondary antibodies, and measured for fluorescence by flow cytometry. Values are mean 6 SEM, n = 9, *indicates p,.05 by
two tailed Mann- Whitney’s t-test. (B) Representative fluorescence overlay for collagen staining. The cells in the left plot were stained with isotype
control primary antibodies, while the cells in the right plot were stained with anti-collagen primary antibodies. Red indicates trypsin-treated cells,
while black indicates no trypsin treatment of the cells.
doi:10.1371/journal.pone.0070795.g007
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inhibited fibrocyte differentiation, presumably due to the presence
of serum amyloid P (SAP) in the serum (Figure 8A). Compared to
no trypsin, trypsin-treated serum increased fibrocyte differentia-
tion. When the serum was depleted of albumin (Figures 8B and
8C), the serum also inhibited fibrocyte differentiation, and
compared to no trypsin, trypsin treatment did not cause an
increase in the number of fibrocytes (Figure 8A). Compared to the
no-trypsin control, in media containing 12.5% human serum,
trypsin concentrations between 5 and 20 mg/ml increased
fibrocyte differentiation, while the same concentrations of trypsin
in albumin-depleted serum media did not increase fibrocyte
differentiation (Figure 8D). These results indicate that trypsin
potentiation of fibrocyte differentiation in serum requires albumin.
Discussion
Trypsin speeds the healing of dermal wounds [48–54]. Albumin
is a major component of serum, and a trypsin-treated extract of
serum potentiates wound healing [49]. In this report, we showed
that trypsin potentiates monocyte differentiation into fibrocytes in
culture and that albumin is necessary for this potentiation to occur.
This then suggests that topical trypsin and trypsin-treated serum
potentiates wound healing by tryptic fragments of albumin
potentiating fibrocyte differentiation.
Trypsin inhibitors in the culture medium of PBMC caused more
trypsin to be necessary to potentiate fibrocyte differentiation,
indicating that trypsin’s enzymatic activity is the key factor in
albumin digestion and fibrocyte potentiation. Soybean trypsin
inhibitor is a slow-binding but nearly irreversible inhibitor of
trypsin’s enzymatic activity [59]. Soybean trypsin inhibitor
stoichiometrically binds trypsin, and the amount of soybean-
trypsin inhibitor added to the trypsin-containing PBMC cultures at
higher concentrations was in excess of the total amount of trypsin
added. Human serum also contains reversible protease inhibitors
with less binding efficacy for trypsin than soybean inhibitor
[60,61]. When mixed and immediately added to albumin-
containing medium, not even the highest concentration of soybean
inhibitor or serum (Figures 3B and 8D) completely abrogated
trypsin’s albumin-induced fibrocyte potentiation, suggesting that
transient trypsinization is enough to digest albumin and induce
fibrocyte differentiation.
Increased fibrocyte formation correlates with increased fibrosis
[62] and faster wound healing [16], and protein additives to
wound dressings can improve the wound healing response [16].
Chronic non-healing wounds are often resistant to more usual
treatment dressings [6,7]. Chronic wounds are associated not only
with infection, age, and diabetes, but also with decreased albumin
concentrations in the wound area [24–27]. An intriguing
possibility is that if albumin degradation products in wounds
potentiate fibrocyte differentiation, the decreased albumin con-
centrations in the chronic wounds might result in lower levels of
the albumin degradation products in the chronic wounds, resulting
in lower levels of fibrocyte differentiation.
Trypsin at ,50 mg/L (50 mg/ml) has been used to produce a
lyophilized, trypsinized serum for wound treatment [49]. We
observed that 5–20 mg/ml trypsin added to 12.5% serum
potentiates fibrocyte differentiation (Figure 8D). This would then
correspond to 40–160 mg/ml trypsin in 100% serum, which
corresponds to the trypsin concentration used for the wound-
healing product.
Proteinases have previously been implicated in interactions with
proteinase-activated receptors (PARs) [45]. PARs are activated by
cleavage of a small peptide from the surface of the receptor by a
serine protease, usually trypsin or chymotrypsin [45]. Research on
Figure 8. Trypsinized human serum containing albumin
potentiates fibrocyte differentiation. (A) TPCK-treated trypsin-
coated agarose beads were used to digest human serum and albumin-
depleted human serum, which were then added to PBMC in protein-
free media at the indicated concentrations for 5 days, after which the
cells were air-dried, stained, counted for fibrocyte differentiation. Values
are mean 6 SEM, n = 7 for serum, n = 4 for depleted serum. Compared
to the trypsinized depleted serum, trypsinized serum significantly
increased the number of fibrocytes: *indicates p,.05 by a two-tailed
Mann-Whitney’s t-test. Compared to depleted serum, trypsinized
depleted serum did not significantly increase fibrocyte number by a
two-tailed Mann-Whitney’s t-test. (B) Albumin-depleted serum shows
less albumin, but a similar protein pattern to human serum, when both
are run at 1:10 dilutions on a silver stained 4–20% SDS-PAGE gel. (C) A
Western blot of serum and albumin-depleted serum stained with anti
human-albumin antibodies. (D) Trypsin was added to PBMC in a 12.5%
serum containing medium, and a 12.5% albumin-depleted serum
containing medium, at the indicated concentrations for 5 days, after
which the cells were air-dried, stained, counted for fibrocyte
differentiation. Values are mean 6 SEM, n = 7 for serum, n = 4 for
depleted serum. Compared to the trypsinized depleted serum,
trypsinized serum significantly increased the number of fibrocytes:
*indicates p,.05 by a two-tailed Mann-Whitney’s t-test.
doi:10.1371/journal.pone.0070795.g008
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PARs has been primarily confined to mesenchymal cells, usually in
the digestive tract where trypsin is a common enzyme [63–66].
Since cells treated with trypsin in protein-free media do not have
increased fibrocyte formation, and chymotrypsin does not
potentiate fibrocyte differentiation, trypsin’s effect on fibrocyte
differentiation does not appear to be mediated by proteinase
activated receptors.
Monocyte-derived fibrocytes are found in wound healing
environments [10–12] and at tissue near a tumor edge [67–69],
both areas of increased serine proteinase activity [38,70–73]. For
instance, marapsin, a protease that also cleaves at arginine, is up-
regulated in wound healing environments [70]. An intriguing
possibility is that endogenous proteases, by generating tryptic
fragments of albumin, help to potentiate fibrocyte differentiation
in wounds and tissues near a tumor edge.
Taken together, our results suggest that topical trypsin and
trypsinized albumin potentiate wound healing at least in part by
potentiating fibrocyte differentiation. While trypsin has been used
in the treatment of burns and in wound dressings for more than 50
years, a mixture of albumin and trypsin may further speed wound
healing, especially when applied to chronic wounds deficient in
albumin [24–27].
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